Core Viewpoint - The company, Koyuan Pharmaceutical, has significantly revised its profit forecast for 2025, projecting a net profit of 12.09 million to 18.13 million yuan, representing a year-on-year decline of 70% to 80% due to legal issues involving its subsidiary [1][2][3] Financial Performance - The revised profit forecast indicates a drastic reduction from the previous estimate of 27.20 million to 39.29 million yuan, which was a decline of 35% to 55% year-on-year [2] - The company has experienced a continuous decline in net profit for three consecutive years, with net profits of 7.70 million yuan in 2023 and 6.00 million yuan in 2024, marking declines of 15.60% and 21.54% respectively [4] - The company’s net profit for 2025 is expected to continue this downward trend, following a pattern of declining profits since its IPO [4] Legal Issues - The profit revision is primarily due to a civil judgment against its subsidiary, Shandong Linuo Pharmaceutical, which is required to pay 16.11 million yuan in damages related to a contract dispute [3] Management Instability - The company has faced significant management turnover since its IPO, with three chairpersons and four general managers changing within a short period, raising concerns about leadership stability [1][9] - The frequent changes in key management positions, including the financial director and supervisory board chairman, have occurred within a few months, indicating potential internal challenges [9] Strategic Moves - Koyuan Pharmaceutical attempted to enhance its performance through an acquisition of Hongjitang, a company specializing in traditional Chinese medicine, but ultimately terminated the acquisition due to changing market conditions [7][8]
科源制药受诉讼拖累盈利降逾70% 三年三换董事长收购失败待突围